Use of a biomarker in exposure-response analysis to support dose selection for fingolimod

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 8, 2013, Pages

  Lee, J Y ^a   Wang, Y ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; FINGOLIMOD;

ARTICLE; BLOOD SAMPLING; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; EFFECT SIZE; EXPOSURE RESPONSE ANALYSIS; HUMAN; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL;

EID: 84883324473     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.44     Document Type: Article

References (13)

1. Fingolimod http://www.accessdata.fda.gov/scripts/cder/drugsat.fda/index. cfm?fuseaction=Search.DrugDetails .
2. Cohen, J.A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
3. Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N. & Baumruker, T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278, 47408-47415 (2003).
4. Paugh, S.W., Payne, S.G., Barbour, S.E., Milstien, S. & Spiegel, S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554, 189-193 (2003).
5. Berdyshev, E.V. et al. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J. Biol. Chem. 284, 5467-5477 (2009).
6. Saab, G., Almony, A., Blinder, K.J., Schuessler, R. & Brennan, D.C. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch. Ophthalmol. 126, 140-141 (2008).
7. Westhoff, T.H. et al. The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. Nephrol. Dial. Transplant. 22, 2354-2358 (2007).
8. Guidance for Industry, "Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications". http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm .
9. Bhattaram, V.A. et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 7, E503-E512 (2005).
10. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
11. Lee, J.Y. et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 50, 627-635 (2011).
12. Fingolimod Drug Approval Package http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2010/022527Orig1s000TOC.cfm .
13. Efron, B. Nonparametric estimates of standard error: the jackknife, the bootstrap and other methods. Biometrika 68, 589-599 (1981).